Research ExplorerPublicationsTranscatheter aortic valve implantation with the 34 mm self-...

Transcatheter aortic valve implantation with the 34 mm self-expanding CoreValve Evolut R: initial experience in 101 patients from a multicentre registry

Standard

Transcatheter aortic valve implantation with the 34 mm self-expanding CoreValve Evolut R: initial experience in 101 patients from a multicentre registry. / Kuhn, Christian; Frerker, Christian; Meyer, Anne-Kathrin; Kurz, Thomas; Schäfer, Ulrich; Deuschl, Florian; Abdel-Wahab, Mohammed; Schewel, Dimitry; Elghalban, Ahmed; Kuck, Karl-Heinz; Frey, Norbert; Frank, Derk.

In: EUROINTERVENTION, Vol. 14, No. 3, 08.06.2018, p. e301-e305.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kuhn, C, Frerker, C, Meyer, A-K, Kurz, T, Schäfer, U, Deuschl, F, Abdel-Wahab, M, Schewel, D, Elghalban, A, Kuck, K-H, Frey, N & Frank, D 2018, 'Transcatheter aortic valve implantation with the 34 mm self-expanding CoreValve Evolut R: initial experience in 101 patients from a multicentre registry', EUROINTERVENTION, vol. 14, no. 3, pp. e301-e305. https://doi.org/10.4244/EIJ-D-17-01153

APA

Kuhn, C., Frerker, C., Meyer, A-K., Kurz, T., Schäfer, U., Deuschl, F., Abdel-Wahab, M., Schewel, D., Elghalban, A., Kuck, K-H., Frey, N., & Frank, D. (2018). Transcatheter aortic valve implantation with the 34 mm self-expanding CoreValve Evolut R: initial experience in 101 patients from a multicentre registry. EUROINTERVENTION, 14(3), e301-e305. https://doi.org/10.4244/EIJ-D-17-01153

Vancouver

Kuhn C, Frerker C, Meyer A-K, Kurz T, Schäfer U, Deuschl F et al. Transcatheter aortic valve implantation with the 34 mm self-expanding CoreValve Evolut R: initial experience in 101 patients from a multicentre registry. EUROINTERVENTION. 2018 Jun 8;14(3):e301-e305. https://doi.org/10.4244/EIJ-D-17-01153

Bibtex

@article{c59bde6b1d9f4959890ebf82f8eb77db,
title = "Transcatheter aortic valve implantation with the 34 mm self-expanding CoreValve Evolut R: initial experience in 101 patients from a multicentre registry",
abstract = "AIMS: The recently released Medtronic CoreValve Evolut R 34 mm is the largest self-expanding transcatheter heart valve ever developed. Clinical data for this device size are scarce. We therefore aimed to evaluate the clinical performance and safety of the new device.METHODS AND RESULTS: We report on the first 101 consecutive patients treated with transfemoral transcatheter aortic valve implantation (TAVI) using the 34 mm Evolut R device in a multicentre registry. Clinical parameters were determined before the procedure and echocardiography was performed at baseline and discharge. VARC-2 criteria were assessed at 30 days. Mean age was 80.7 years; mean logistic EuroSCORE was 19.8%. Procedural duration was 71.6 min. Echocardiography at discharge revealed a mean AVA of 2.0 cm2, moderate aortic regurgitation (AR) in 4.0% and severe AR in 1.0%. VARC-2 device success was achieved in 92.1%, while the early safety endpoint occurred in 11 patients (10.9%). New permanent pacemakers were implanted in 17 patients (18.7%). Thirty-day mortality was 2.0%, a stroke occurred in 3.0%, with a disabling stroke in one patient. The incidence of major vascular complications and bleeding was 1.0% and 5.0%, respectively.CONCLUSIONS: Initial experience with the new self-expanding CoreValve Evolut R 34 mm valve is characterised by high procedural success, good haemodynamic performance and a low early complication rate.",
keywords = "Aged, 80 and over, Aortic Valve, Aortic Valve Stenosis, Heart Valve Prosthesis, Humans, Prosthesis Design, Registries, Transcatheter Aortic Valve Replacement, Treatment Outcome",
author = "Christian Kuhn and Christian Frerker and Anne-Kathrin Meyer and Thomas Kurz and Ulrich Sch{\"a}fer and Florian Deuschl and Mohammed Abdel-Wahab and Dimitry Schewel and Ahmed Elghalban and Karl-Heinz Kuck and Norbert Frey and Derk Frank",
year = "2018",
month = jun,
day = "8",
doi = "10.4244/EIJ-D-17-01153",
language = "English",
volume = "14",
pages = "e301--e305",
journal = "EUROINTERVENTION",
issn = "1774-024X",
publisher = "EUROPA EDITION",
number = "3",

}

RIS

TY - JOUR

T1 - Transcatheter aortic valve implantation with the 34 mm self-expanding CoreValve Evolut R: initial experience in 101 patients from a multicentre registry

AU - Kuhn, Christian

AU - Frerker, Christian

AU - Meyer, Anne-Kathrin

AU - Kurz, Thomas

AU - Schäfer, Ulrich

AU - Deuschl, Florian

AU - Abdel-Wahab, Mohammed

AU - Schewel, Dimitry

AU - Elghalban, Ahmed

AU - Kuck, Karl-Heinz

AU - Frey, Norbert

AU - Frank, Derk

PY - 2018/6/8

Y1 - 2018/6/8

N2 - AIMS: The recently released Medtronic CoreValve Evolut R 34 mm is the largest self-expanding transcatheter heart valve ever developed. Clinical data for this device size are scarce. We therefore aimed to evaluate the clinical performance and safety of the new device.METHODS AND RESULTS: We report on the first 101 consecutive patients treated with transfemoral transcatheter aortic valve implantation (TAVI) using the 34 mm Evolut R device in a multicentre registry. Clinical parameters were determined before the procedure and echocardiography was performed at baseline and discharge. VARC-2 criteria were assessed at 30 days. Mean age was 80.7 years; mean logistic EuroSCORE was 19.8%. Procedural duration was 71.6 min. Echocardiography at discharge revealed a mean AVA of 2.0 cm2, moderate aortic regurgitation (AR) in 4.0% and severe AR in 1.0%. VARC-2 device success was achieved in 92.1%, while the early safety endpoint occurred in 11 patients (10.9%). New permanent pacemakers were implanted in 17 patients (18.7%). Thirty-day mortality was 2.0%, a stroke occurred in 3.0%, with a disabling stroke in one patient. The incidence of major vascular complications and bleeding was 1.0% and 5.0%, respectively.CONCLUSIONS: Initial experience with the new self-expanding CoreValve Evolut R 34 mm valve is characterised by high procedural success, good haemodynamic performance and a low early complication rate.

AB - AIMS: The recently released Medtronic CoreValve Evolut R 34 mm is the largest self-expanding transcatheter heart valve ever developed. Clinical data for this device size are scarce. We therefore aimed to evaluate the clinical performance and safety of the new device.METHODS AND RESULTS: We report on the first 101 consecutive patients treated with transfemoral transcatheter aortic valve implantation (TAVI) using the 34 mm Evolut R device in a multicentre registry. Clinical parameters were determined before the procedure and echocardiography was performed at baseline and discharge. VARC-2 criteria were assessed at 30 days. Mean age was 80.7 years; mean logistic EuroSCORE was 19.8%. Procedural duration was 71.6 min. Echocardiography at discharge revealed a mean AVA of 2.0 cm2, moderate aortic regurgitation (AR) in 4.0% and severe AR in 1.0%. VARC-2 device success was achieved in 92.1%, while the early safety endpoint occurred in 11 patients (10.9%). New permanent pacemakers were implanted in 17 patients (18.7%). Thirty-day mortality was 2.0%, a stroke occurred in 3.0%, with a disabling stroke in one patient. The incidence of major vascular complications and bleeding was 1.0% and 5.0%, respectively.CONCLUSIONS: Initial experience with the new self-expanding CoreValve Evolut R 34 mm valve is characterised by high procedural success, good haemodynamic performance and a low early complication rate.

KW - Aged, 80 and over

KW - Aortic Valve

KW - Aortic Valve Stenosis

KW - Heart Valve Prosthesis

KW - Humans

KW - Prosthesis Design

KW - Registries

KW - Transcatheter Aortic Valve Replacement

KW - Treatment Outcome

U2 - 10.4244/EIJ-D-17-01153

DO - 10.4244/EIJ-D-17-01153

M3 - SCORING: Journal article

C2 - 29808820

VL - 14

SP - e301-e305

JO - EUROINTERVENTION

JF - EUROINTERVENTION

SN - 1774-024X

IS - 3

ER -